BioCentury
ARTICLE | Company News

Oct. 7 Company Quick Takes: Editas-MaxCyte, Goldfinch-Takeda, Prometheus-Takeda, DBV and Galderma

October 7, 2019 11:17 PM UTC
Updated on Oct 9, 2019 at 12:45 AM UTC

Editas licenses MaxCyte tech to develop engineered cell medicines
Editas Medicine Inc. (NASDAQ:EDIT) licensed non-exclusive clinical and commercial rights to Flow Electroporation technology and ExPERT instruments from MaxCyte Inc. (LSE:MXCT) to develop engineered cell medicines, including EDIT-301, a CRISPR therapy that is in preclinical testing for sickle cell disease and β thalassemia. Editas will develop up to five therapies, including four immuno-oncology therapies. MaxCyte is eligible to receive milestones, sales payments and licensing fees. Details are not disclosed.

Goldfinch licenses CB1 inhibitor for kidney diseases from Takeda
Goldfinch Biopharma Inc. licensed a peripherally restricted cannabinoid receptor 1 (CB1) mAb from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK). Goldfinch will be responsible for development and commercialization to treat rare and metabolic kidney diseases worldwide; Takeda has an option to negotiate Japanese rights before pivotal trials begin. Goldfinch plans to submit an IND for the compound, which it has renamed GFB-024, in 2H20. Financial terms were not disclosed. (see "Kidney is the New Liver")...